ACYCLOVIR VERSUS VIDARABINE IN HERPES SIMPLEX ENCEPHALITIS: Randomised Multicentre Study in Consecutive Swedish Patients
127 patients with suspected herpes simplex encephalitis (HSE) were entered in a prospective randomised study of acyclovir 10 mg/kg 8-hourly versus vidarabine 15 mg/kg daily for 10 days. The patients were consecutive and nearly all Swedish cases of HSE were included; they were treated in six universi...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1984-09, Vol.324 (8405), p.707-711 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 711 |
|---|---|
| container_issue | 8405 |
| container_start_page | 707 |
| container_title | The Lancet (British edition) |
| container_volume | 324 |
| creator | Sköldenberg, Birgit Alestig, Kjell Burman, Lars Forkman, Anders Lövgren, Kerstin Norrby, Ragnar Stiernstedt, Göran Forsgren, Marianne Bergström, Thomas Dahlqvist, Erik Frydén, Aril Norlin, Karin Olding-Stenkvist, Isabeth Uhnoo, Ingrid De Vahl, Kicks |
| description | 127 patients with suspected herpes simplex encephalitis (HSE) were entered in a prospective randomised study of acyclovir 10 mg/kg 8-hourly versus vidarabine 15 mg/kg daily for 10 days. The patients were consecutive and nearly all Swedish cases of HSE were included; they were treated in six university infectious diseases departments. The diagnosis of HSE was verified by brain biopsy and/or antibody responses in serum and cerebrospinal fluid. Of 53 confirmed cases of HSE (corresponding to 2·3 cases per million inhabitants per year in Sweden), 51 (27 acyclovir, 24 vidarabine) were evaluable for analysis of efficacy. The mortality was 19% in the acyclovir-treated group versus 50% in the vidarabine group (p=0·04). At 6 months of observation 15 (56%) of 27 acyclovir-treated patients had returned to normal life compared with 3 (13%) of 24 vidarabine-treated patients (p = 0·002); and the numbers who died or had severe sequelae were 9 (33%) and 19 (76%), respectively (p=0·005). No important or new adverse events were recognised. |
| doi_str_mv | 10.1016/S0140-6736(84)92623-0 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_8902362</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673684926230</els_id><sourcerecordid>S0140673684926230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c229t-fdd6f7f69dda875d4c3c38e0dfcdf81d5b7e09f2220ab6f6b21f5550a3415eef3</originalsourceid><addsrcrecordid>eNo9kE9LwzAYh4MoOKcfQcjBgx6qSZqmrReptbpCnaXdxjyFLH8wMrvRdNN9ezsVTy-8PPx4eAA4x-gaI8xuaoQp8ljos8uIXsWEEd9DB2CAaUi9gIbzQzD4R47BiXPvCCHKUDAAX0n6mhYvs7yCs6yqpzWc5Q9Jldzn4wzmYzjKqjKrYZ0_l0U2h9k4zcpRUuSTvL6FlWjU6sM6reDzZtlZqZuu1bDuNmoHbQPTVeO03HR22z8_tbLuDZaisz3mTsGREUunz_7uEEwfs0k68oqXpzxNCk8SEneeUYqZ0LBYKRGFgaLSl36kkTJSmQirYBFqFBtCCBILZtiCYBMEARI-xYHWxh-Ci9_dtXBSLE0rGmkdX7f2Q7Q7HsWI-H2wIbj7xXTvsrW65U72nrKXbrXsuFpZjhHf9-Y_vfk-Jo8o_-nNkf8NzMFxyw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>ACYCLOVIR VERSUS VIDARABINE IN HERPES SIMPLEX ENCEPHALITIS: Randomised Multicentre Study in Consecutive Swedish Patients</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Sköldenberg, Birgit ; Alestig, Kjell ; Burman, Lars ; Forkman, Anders ; Lövgren, Kerstin ; Norrby, Ragnar ; Stiernstedt, Göran ; Forsgren, Marianne ; Bergström, Thomas ; Dahlqvist, Erik ; Frydén, Aril ; Norlin, Karin ; Olding-Stenkvist, Isabeth ; Uhnoo, Ingrid ; De Vahl, Kicks</creator><creatorcontrib>Sköldenberg, Birgit ; Alestig, Kjell ; Burman, Lars ; Forkman, Anders ; Lövgren, Kerstin ; Norrby, Ragnar ; Stiernstedt, Göran ; Forsgren, Marianne ; Bergström, Thomas ; Dahlqvist, Erik ; Frydén, Aril ; Norlin, Karin ; Olding-Stenkvist, Isabeth ; Uhnoo, Ingrid ; De Vahl, Kicks</creatorcontrib><description>127 patients with suspected herpes simplex encephalitis (HSE) were entered in a prospective randomised study of acyclovir 10 mg/kg 8-hourly versus vidarabine 15 mg/kg daily for 10 days. The patients were consecutive and nearly all Swedish cases of HSE were included; they were treated in six university infectious diseases departments. The diagnosis of HSE was verified by brain biopsy and/or antibody responses in serum and cerebrospinal fluid. Of 53 confirmed cases of HSE (corresponding to 2·3 cases per million inhabitants per year in Sweden), 51 (27 acyclovir, 24 vidarabine) were evaluable for analysis of efficacy. The mortality was 19% in the acyclovir-treated group versus 50% in the vidarabine group (p=0·04). At 6 months of observation 15 (56%) of 27 acyclovir-treated patients had returned to normal life compared with 3 (13%) of 24 vidarabine-treated patients (p = 0·002); and the numbers who died or had severe sequelae were 9 (33%) and 19 (76%), respectively (p=0·005). No important or new adverse events were recognised.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(84)92623-0</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>The Lancet (British edition), 1984-09, Vol.324 (8405), p.707-711</ispartof><rights>1984</rights><rights>1985 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c229t-fdd6f7f69dda875d4c3c38e0dfcdf81d5b7e09f2220ab6f6b21f5550a3415eef3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0140-6736(84)92623-0$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8902362$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Sköldenberg, Birgit</creatorcontrib><creatorcontrib>Alestig, Kjell</creatorcontrib><creatorcontrib>Burman, Lars</creatorcontrib><creatorcontrib>Forkman, Anders</creatorcontrib><creatorcontrib>Lövgren, Kerstin</creatorcontrib><creatorcontrib>Norrby, Ragnar</creatorcontrib><creatorcontrib>Stiernstedt, Göran</creatorcontrib><creatorcontrib>Forsgren, Marianne</creatorcontrib><creatorcontrib>Bergström, Thomas</creatorcontrib><creatorcontrib>Dahlqvist, Erik</creatorcontrib><creatorcontrib>Frydén, Aril</creatorcontrib><creatorcontrib>Norlin, Karin</creatorcontrib><creatorcontrib>Olding-Stenkvist, Isabeth</creatorcontrib><creatorcontrib>Uhnoo, Ingrid</creatorcontrib><creatorcontrib>De Vahl, Kicks</creatorcontrib><title>ACYCLOVIR VERSUS VIDARABINE IN HERPES SIMPLEX ENCEPHALITIS: Randomised Multicentre Study in Consecutive Swedish Patients</title><title>The Lancet (British edition)</title><description>127 patients with suspected herpes simplex encephalitis (HSE) were entered in a prospective randomised study of acyclovir 10 mg/kg 8-hourly versus vidarabine 15 mg/kg daily for 10 days. The patients were consecutive and nearly all Swedish cases of HSE were included; they were treated in six university infectious diseases departments. The diagnosis of HSE was verified by brain biopsy and/or antibody responses in serum and cerebrospinal fluid. Of 53 confirmed cases of HSE (corresponding to 2·3 cases per million inhabitants per year in Sweden), 51 (27 acyclovir, 24 vidarabine) were evaluable for analysis of efficacy. The mortality was 19% in the acyclovir-treated group versus 50% in the vidarabine group (p=0·04). At 6 months of observation 15 (56%) of 27 acyclovir-treated patients had returned to normal life compared with 3 (13%) of 24 vidarabine-treated patients (p = 0·002); and the numbers who died or had severe sequelae were 9 (33%) and 19 (76%), respectively (p=0·005). No important or new adverse events were recognised.</description><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1984</creationdate><recordtype>article</recordtype><recordid>eNo9kE9LwzAYh4MoOKcfQcjBgx6qSZqmrReptbpCnaXdxjyFLH8wMrvRdNN9ezsVTy-8PPx4eAA4x-gaI8xuaoQp8ljos8uIXsWEEd9DB2CAaUi9gIbzQzD4R47BiXPvCCHKUDAAX0n6mhYvs7yCs6yqpzWc5Q9Jldzn4wzmYzjKqjKrYZ0_l0U2h9k4zcpRUuSTvL6FlWjU6sM6reDzZtlZqZuu1bDuNmoHbQPTVeO03HR22z8_tbLuDZaisz3mTsGREUunz_7uEEwfs0k68oqXpzxNCk8SEneeUYqZ0LBYKRGFgaLSl36kkTJSmQirYBFqFBtCCBILZtiCYBMEARI-xYHWxh-Ci9_dtXBSLE0rGmkdX7f2Q7Q7HsWI-H2wIbj7xXTvsrW65U72nrKXbrXsuFpZjhHf9-Y_vfk-Jo8o_-nNkf8NzMFxyw</recordid><startdate>19840929</startdate><enddate>19840929</enddate><creator>Sköldenberg, Birgit</creator><creator>Alestig, Kjell</creator><creator>Burman, Lars</creator><creator>Forkman, Anders</creator><creator>Lövgren, Kerstin</creator><creator>Norrby, Ragnar</creator><creator>Stiernstedt, Göran</creator><creator>Forsgren, Marianne</creator><creator>Bergström, Thomas</creator><creator>Dahlqvist, Erik</creator><creator>Frydén, Aril</creator><creator>Norlin, Karin</creator><creator>Olding-Stenkvist, Isabeth</creator><creator>Uhnoo, Ingrid</creator><creator>De Vahl, Kicks</creator><general>Elsevier Ltd</general><general>Lancet</general><scope>IQODW</scope></search><sort><creationdate>19840929</creationdate><title>ACYCLOVIR VERSUS VIDARABINE IN HERPES SIMPLEX ENCEPHALITIS: Randomised Multicentre Study in Consecutive Swedish Patients</title><author>Sköldenberg, Birgit ; Alestig, Kjell ; Burman, Lars ; Forkman, Anders ; Lövgren, Kerstin ; Norrby, Ragnar ; Stiernstedt, Göran ; Forsgren, Marianne ; Bergström, Thomas ; Dahlqvist, Erik ; Frydén, Aril ; Norlin, Karin ; Olding-Stenkvist, Isabeth ; Uhnoo, Ingrid ; De Vahl, Kicks</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c229t-fdd6f7f69dda875d4c3c38e0dfcdf81d5b7e09f2220ab6f6b21f5550a3415eef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1984</creationdate><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sköldenberg, Birgit</creatorcontrib><creatorcontrib>Alestig, Kjell</creatorcontrib><creatorcontrib>Burman, Lars</creatorcontrib><creatorcontrib>Forkman, Anders</creatorcontrib><creatorcontrib>Lövgren, Kerstin</creatorcontrib><creatorcontrib>Norrby, Ragnar</creatorcontrib><creatorcontrib>Stiernstedt, Göran</creatorcontrib><creatorcontrib>Forsgren, Marianne</creatorcontrib><creatorcontrib>Bergström, Thomas</creatorcontrib><creatorcontrib>Dahlqvist, Erik</creatorcontrib><creatorcontrib>Frydén, Aril</creatorcontrib><creatorcontrib>Norlin, Karin</creatorcontrib><creatorcontrib>Olding-Stenkvist, Isabeth</creatorcontrib><creatorcontrib>Uhnoo, Ingrid</creatorcontrib><creatorcontrib>De Vahl, Kicks</creatorcontrib><collection>Pascal-Francis</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sköldenberg, Birgit</au><au>Alestig, Kjell</au><au>Burman, Lars</au><au>Forkman, Anders</au><au>Lövgren, Kerstin</au><au>Norrby, Ragnar</au><au>Stiernstedt, Göran</au><au>Forsgren, Marianne</au><au>Bergström, Thomas</au><au>Dahlqvist, Erik</au><au>Frydén, Aril</au><au>Norlin, Karin</au><au>Olding-Stenkvist, Isabeth</au><au>Uhnoo, Ingrid</au><au>De Vahl, Kicks</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ACYCLOVIR VERSUS VIDARABINE IN HERPES SIMPLEX ENCEPHALITIS: Randomised Multicentre Study in Consecutive Swedish Patients</atitle><jtitle>The Lancet (British edition)</jtitle><date>1984-09-29</date><risdate>1984</risdate><volume>324</volume><issue>8405</issue><spage>707</spage><epage>711</epage><pages>707-711</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>127 patients with suspected herpes simplex encephalitis (HSE) were entered in a prospective randomised study of acyclovir 10 mg/kg 8-hourly versus vidarabine 15 mg/kg daily for 10 days. The patients were consecutive and nearly all Swedish cases of HSE were included; they were treated in six university infectious diseases departments. The diagnosis of HSE was verified by brain biopsy and/or antibody responses in serum and cerebrospinal fluid. Of 53 confirmed cases of HSE (corresponding to 2·3 cases per million inhabitants per year in Sweden), 51 (27 acyclovir, 24 vidarabine) were evaluable for analysis of efficacy. The mortality was 19% in the acyclovir-treated group versus 50% in the vidarabine group (p=0·04). At 6 months of observation 15 (56%) of 27 acyclovir-treated patients had returned to normal life compared with 3 (13%) of 24 vidarabine-treated patients (p = 0·002); and the numbers who died or had severe sequelae were 9 (33%) and 19 (76%), respectively (p=0·005). No important or new adverse events were recognised.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S0140-6736(84)92623-0</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1984-09, Vol.324 (8405), p.707-711 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_pascalfrancis_primary_8902362 |
| source | ScienceDirect Journals (5 years ago - present) |
| subjects | Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Medical sciences Pharmacology. Drug treatments |
| title | ACYCLOVIR VERSUS VIDARABINE IN HERPES SIMPLEX ENCEPHALITIS: Randomised Multicentre Study in Consecutive Swedish Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A47%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ACYCLOVIR%20VERSUS%20VIDARABINE%20IN%20HERPES%20SIMPLEX%20ENCEPHALITIS:%20Randomised%20Multicentre%20Study%20in%20Consecutive%20Swedish%20Patients&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Sk%C3%B6ldenberg,%20Birgit&rft.date=1984-09-29&rft.volume=324&rft.issue=8405&rft.spage=707&rft.epage=711&rft.pages=707-711&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(84)92623-0&rft_dat=%3Celsevier_pasca%3ES0140673684926230%3C/elsevier_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0140673684926230&rfr_iscdi=true |